Spinal muscular atrophy (SMA) is caused by insufficient levels of the survival motor neuron protein SMN. The SMN locus on chromosome 5q13 contains two inverted copies of SMN called SMN1 and SMN2 which are 99% identical at the amino acid level. SMN1 is a fully functional protein and SMN2 skips exon 7 90% of the time. Skipping of exon 7 produces non-functional protein product. 10% of the SMN2 protein includes exon 7 and is fully functional. In the SMA disease state, mutations in the SMN1 locus are the cause of the disease state. Because only 10% of SMN2 is of the fully functional form, it is not sufficient to overcome the deficiency produced by the loss of the SMN1 product. A therapy that either increases the amount of SMN2 product made increases the inclusion of exon 7 has been proposed for the treatment of SMA. We have designed an assay to identify small molecules that can increase the amount of functional SMN2 product by appending a luciferase reporter gene after the native SMN2 gene, such that inclusion of exon 7 in the expressed product places the luciferase sequence in frame, thus generating functional luciferase enzyme. One potential source of false positives in the primary screening assay is stabilization of the reporter luciferase via direct binding. This assay attempts to identify such compounds by screening directly for luciferase activity in the absence of the cellular system. The primary screen utilizes a luciferase reporter gene assay, combining the promoter and splicing based cassettes in tandem with the major portion of the native SMN1 cDNA, and then transfected into HEK293 cells. Compounds that modulate luciferase signal presumably modulate expression of native SMN1 expression. In this assay, we utilize purified firefly luciferase in lieu of a cellular reporter to identify compounds interacting directly with luciferase in the primary screen. Sequence, Parameter, Value, Description (1) Reagent, 2.5 uL, Enzyme in buffer (note A) (2) Compound, 23 nL, From stock solutions (3) Time, 5 minutes, Room temp (4) Reagent#2.5 ul, Luciferase detection reagent  (note B) (5) Detector, 1 sec integrate, Luminescent read on Viewlux (note C) Sigma enzyme (1 mg) considered to be MW 61,000 diluted in 357 ul assay buffer to 50 uM stock. A - Enzyme and buffer consists of 50 mM Tris-acetate pH 7.6, 10 mM Mg acetate 0.05% BSA, 0.01% Tween and 5 nM firefly luciferase B - Detection reagent = britelite plus diluted 1:10 in PBS C - Viewlux settings were 1 second integration medium sensitivity
bao:BAO_0001077 "1458" ; # "is alternate confirmatory assay of" -> "1458"
bao:BAO_0000812 "1474" ; # "has summary assay" -> "1474"
bao:BAO_0000210 bao:BAO_0000032 ; # "has assay stage" -> "secondary assay"
bao:BAO_0000595 bao:BAO_0000467 ; # "has alternate assay format" -> "alternate assay format"
bao:BAO_0000205 bao:BAO_0000217 ; # "has assay format" -> "biochemical format"
bao:BAO_0000205 bao:BAO_0000224 ; # "has assay format" -> "protein format"
bao:BAO_0000205 bao:BAO_0000357 ; # "has assay format" -> "single protein format"
bao:BAO_0000409 bao:BAO_0000410 ; # "assay measurement type" -> "endpoint assay"
bao:BAO_0002850 bao:BAO_0000534 ; # "has assay readout content" -> "single readout"
bao:BAO_0002851 "single parameter" ; # "has assay readout content parametricity" -> "single parameter"
bao:BA0_0090012 bao:BAO_0000291 ; # "has participant" -> "oxidoreductase" || bao:BAO_0003102 bao:BAO_00020144 ; # "has role" -> "target"
bao:BAO_0002855 bao:BAO_0002735 ; # "is bioassay type of" -> "luciferase enzyme activity assay"
bao:BAO_0000212 bao:BAO_0000124 ; # "has assay method" -> "enzyme activity measurement method"
bao:BAO_0000212 bao:BAO_0000139 ; # "has assay method" -> "direct enzyme activity measurement method"
bao:BAO_0000207 bao:BAO_0000045 ; # "has detection method" -> "luminescence method"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Identification of Enhancers of SMN2 Splice Variant Expression" ; # "screening campaign name" -> "Identification of Enhancers of SMN2 Splice Variant Expression"
bao:BAO_0002853 "Counterscreen Assay for Enhancers of SMN2 Splice Variant Expression: Interaction with Luciferase Reporter" ; # "has assay title" -> "Counterscreen Assay for Enhancers of SMN2 Splice Variant Expression: Interaction with Luciferase Reporter"
bao:BAO_0002854 bao:BAO_0000010 ; # "has bioassay type" -> "functional"
bao:BAO_0002863 bao:BAO_0000535 ; # "has concentration throughput" -> "multiple concentration"
bao:BAO_0000109 "25 degree celsius" ; # "has temperature value" -> "25 degree celsius"
bao:BAO_0002833 "5 minute" ; # "has incubation time value" -> "5 minute"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Elliot Androphy" ; # "material entity assay provider" -> "Elliot Androphy" || bao:BAO_0003102 bao:BAO_0000027 ; # "has role" -> "assay provider"
bao:BAO_0002020 bao:BAO_0000372 ; # "has assay phase characteristic" -> "homogeneous phase"
bao:BA0_0090012 bao:BAO_0001038 ; # "has participant" -> "Tween 20" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_27780> ; # "has role" -> "detergent"
bao:BA0_0090012 bao:BAO_0000776 ; # "has participant" -> "Adenosine triphosphate" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_25078> ; # "has role" -> "luciferin" || bao:BAO_0003102 bao:BAO_00020143 ; # "has role" -> "substrate"
bao:BA0_0090012 bao:BAO_0000141 ; # "has participant" -> "Luciferin 4-monooxygenase"
bao:BAO_0002921 <http://purl.obolibrary.org/obo/NCBITaxon_7054> ; # "has organism" -> "Photinus pyralis"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "P08659" ; # "uniprot ID" -> "P08659"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "7054" ; # "NCBI taxonomy ID" -> "7054"
bao:BAO_0002662 bao:BAO_0002157 ; # "has quality" -> "native form"
bao:BAO_0002897 bao:BAO_0000360 ; # "has preparation method" -> "recombinant expression"
bao:BAO_0002622 bao:BAO_00020127 ; # "has purity value" -> "purified"
bao:BAO_0002000 bao:BAO_0002001 ; # "has measured entity" -> "measured entity"
bao:BAO_0002857 bao:BAO_0002153 ; # "has signal direction" -> "signal increase corresponding to inhibition"
bao:BAO_0000308 bao:BAO_0000686 ; # "has assay kit" -> "britelite plus"
bao:BAO_0000308 bao:BAO_0000248 ; # "has assay kit" -> "assay Kit"
bao:BAO_0000737 bao:BAO_0000297 ; # "has manufacturer" -> "Perkin Elmer" || bao:BAO_0003102 bao:BAO_0002626 ; # "has role" -> "biologics and screening manufacturer"
bao:BA0_0090012 bao:BAO_0000176 ; # "has participant" -> "small molecule" || bao:BAO_0003102 bao:BAO_00020137 ; # "has role" -> "perturbagen"
bao:BAO_0000212 bao:BAO_0000574 ; # "has assay method" -> "single perturbagen"
bao:BAO_0000648 bao:BAO_0000733 ; # "compound library" -> "MLSMR library"
bao:BAO_0002865 bao:BAO_0001046 ; # "uses detection instrument" -> "ViewLux CCD Imager" || bao:BAO_0003102 bao:BAO_0002628 ; # "has role" -> "instrumentation manufacturer"
bao:BAO_0000208 bao:BAO_0000186 ; # "has endpoint" -> "AC50"
bao:BAO_0000337 bao:BAO_0000656 ; # "has percent response" -> "efficacy"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000064> ; # "has concentration unit" -> "micromolar"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "2" ; # "PubChem TID" -> "2"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "3" ; # "PubChem TID" -> "3"
bao:BAO_0000182 <http://purl.org/obo/owl/UO#UO_0000187> ; # "has response unit" -> "percent"
bao:BAO_0002787 "26" ; # "has concentration-point number" -> "26"
bao:BAO_0002845 "1" ; # "has repetition point-number" -> "1"
bao:BAO_0000196 bao:BAO_0000087 ; # "has mode of action" -> "activation"
bao:BAO_0002864 bao:BAO_0000136 ; # "has repetition throughput" -> "single repetition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Uma" ; # "Annotated by" -> "Uma"
